Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer

This is a single-center, prospective, single arm phase II study to evaluate the efficacy and safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as neoadjuvant therapy in operable locally advanced breast cancer patients. The primary objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample size is 30.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: nab-paclitaxel

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Shanghai, China, 200032
    • Fudan University Shanghai Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Female, between 18 and 70 years old
• Life expectancy is more than 12 months
• Breast MRI or ultrasound confirmd tumor over 3cm and biopsy comfirned invasive breast caner of stage II-III (inflammatory breast cancer excluded)
• Not accompanied with other malignancies（except for controlled carcinoma in situ of the cervix or skin basal-cell carcinoma）
• A normal bone marrow: absolute neutrophil count≥1.5*10E9/L, hemoglobin≥100g/L, PLT≥100*10E9/L
• Normal liver and renal functions: AST≤60U/L, total biliruin≤1.5*upper limit of normal, serum creatinine≤110umol/L, urea nitrogen≤7.1mmol/L
• Normal blood coagulation function
• ECOG performance status of 0-1
• Willing to coordinate with a punch biopsy before treatment and accept neoadjuvant therapy
• Women of child-producing potential must agree to use effective contraceptive methods during the study, and a negative serum or urine pregnancy test must be obtained within 7 days prior to administration of the drugs
• Written informed consent
• For HER-2 positive patients, the HER-2 status must be determined by ICH +++ or FISH/CISH. For patients treated with trastuzumb, LVEF≥55% by ultrasonic cardiogram or MUGA scan

Exclusion Criteria:

• Previous systematic or local therapy including chemotherapy for breast cancer
• Distant metastases of breast cancer are observed
• Concurrent uncontrolled lung disease, severe sepsis, active peptic ulcer requring treatment, blood coagulation disorders, serious uncontrolled diabetes, connective tissue disease or bone marrow depression, unable to tolerate neoadjuvant therapy and related treatment
• >Grade 1 peripheral neuropathy caused by any reason
• History of CHF, uncontrolled symptomatic angina, history of arrhythmias or myocardial infarction, poorly controlled hypertension (systolic pressure > 180mmHg or diastlic pressure > 100 mmHg)
• Lactational or gestational breast cancer
• Not willing to accept a punch biopsy before treatment and neoadjuvant therapy
• Psychopath or any other reasons that would preclude compliane with treatment
• Known serious allergy to any of the study drugs or excipients
• Participation in another study requiring administration of an in investigational drug or biological agent at present or recently (within the last 30 days prior to screening visit)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: neoadjuvant	Drug: nab-paclitaxel; nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity; Other Names: Herceptin; Abraxane

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pathological complete response rate	The percentage of patients with a pathological complete response after neoadjuvant therapy	Obtained within six months of the last patient's enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate	The percentage of patients with complete response or partial response after neoadjuvant therapy	Obtained within six months of the last patient's enrollment
Three-year disease free survival	The percentage of patients who survive without breast cancer recurrence or metastases three years after surgery	Obtained within 42 months after last patient's enrollment
Overall survival	The overall survival time of all patients enrolled in the study presented by survival curve and median value	Obtained around 5 years after the last patient's erollment
Safety	List and frequencies of adverse events occured during and one-month after the investigational drug treatment	Obtained around six months after the last patient's enrollment

Collaborators and Investigators

• Sponsor: Shanghai Cancer Hospital, China
• Investigators: Principal Investigator: Zhimin Shao, MD, Fudan University

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (Anticipated): September 1, 2013
• Study Completion (Anticipated): June 1, 2017

Study Registration Dates

• First Submitted: June 19, 2012
• First Submitted That Met QC Criteria: June 19, 2012
• First Posted (Estimate): June 21, 2012

Study Record Updates

• Last Update Posted (Estimate): November 9, 2012
• Last Update Submitted That Met QC Criteria: November 8, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel
• Other Study ID Numbers: ABX-1201